舒利迭联合孟鲁司特对咳嗽变异性哮喘患儿的疗效及其对IL-13,IgE的影响

Abstract

[目的]探讨舒利迭联合孟鲁司特对咳嗽变异性哮喘（CVA）患儿的治疗作用及可能作用机制。[方法]选择80例C V A患儿按数字表法随机分为观察组和对照组，每组40例，观察组给予舒利迭联合孟鲁司特治疗，对照组给予舒利迭治疗，8周后观察两组患儿的临床疗效及治疗前后血清白介素-13（IL-13）、免疫球蛋白E（IgE）的含量变化。[结果]观察组临床总有效率为97．5％、对照组为80．0％，两组临床总有效率比较有统计学差异（ P ＜0．05）；治疗后观察组IL-13、Ig E水平及对照组Ig E水平均下降，与本组治疗前比较差异均有统计学意义（ P ＜0．05），且观察组 IL-13与对照组比较差异有显著性（ P ＜0．05）；治疗前两组血清IL-13、IgE水平间呈正相关（ P＜0．05）。[结论]舒利迭联合孟鲁司特对CVA患儿的疗效显著，可调节其外周血IL-13、Ig E的水平变化。

[Objective]To explore the efficacy of seretide combined with montelukast for the treatment of pediat-ric patients with cough variant asthma (CVA ) and the possible action mechanisms .[Methods]Totally 80 CVA pa-tients were randomly divided into observation group and control group with 40 patients in each group .The observation group received seretide combined with montelukast ,while the control group received seretide .After 8 weeks ,clinical efficacy and serum levels of interleukin-13(IL-13) and immunoglobulin E(IgE) of two groups before and after treat-ment were observed .[Results]Clinical total effective rate of observation group was 97 .5% ,while that of control group was 80 .0% .There was significant difference in total clinical efficiency between two groups ( P<0 .05) .After treatment ,IL-13 and IgE in observation group and IgE levels in control group were decreased ,and there was signifi-cant difference between before and after treatment ( P<0 .05) .There was significant difference in IL-13 between ob-servation group and control group( P<0 .05) .Before treatment ,serum IL-13 of two groups were positively correla-ted with IgE( P<0 .05) .[Conclusion]Seretide combined with montelukast for the treatment of CVA has significant efficacy ,and can regulate the changes of IL-13 and IgE in peripheral blood .